These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 26318164)

  • 1. Reply to Dimitrov et al.: VelociSuite technologies are a foundation for rapid therapeutic antibody development.
    Kyratsous CA; Olson W; Stahl N
    Proc Natl Acad Sci U S A; 2015 Sep; 112(37):E5116. PubMed ID: 26318164
    [No Abstract]   [Full Text] [Related]  

  • 2. No evidence for a superior platform to develop therapeutic antibodies rapidly in response to MERS-CoV and other emerging viruses.
    Dimitrov DS; Jiang S; Ying T; Tseng CT; Zhang L; Yuen KY
    Proc Natl Acad Sci U S A; 2015 Sep; 112(37):E5115. PubMed ID: 26318165
    [No Abstract]   [Full Text] [Related]  

  • 3. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection.
    Pascal KE; Coleman CM; Mujica AO; Kamat V; Badithe A; Fairhurst J; Hunt C; Strein J; Berrebi A; Sisk JM; Matthews KL; Babb R; Chen G; Lai KM; Huang TT; Olson W; Yancopoulos GD; Stahl N; Frieman MB; Kyratsous CA
    Proc Natl Acad Sci U S A; 2015 Jul; 112(28):8738-43. PubMed ID: 26124093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy.
    Tang XC; Marasco WA
    Immunotherapy; 2015; 7(6):591-4. PubMed ID: 26098703
    [No Abstract]   [Full Text] [Related]  

  • 5. Neutralizing the MERS coronavirus threat.
    Haagmans BL; Osterhaus AD
    Sci Transl Med; 2014 May; 6(235):235fs19. PubMed ID: 24807556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus.
    Guo X; Deng Y; Chen H; Lan J; Wang W; Zou X; Hung T; Lu Z; Tan W
    Immunology; 2015 Aug; 145(4):476-84. PubMed ID: 25762305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein.
    Volz A; Kupke A; Song F; Jany S; Fux R; Shams-Eldin H; Schmidt J; Becker C; Eickmann M; Becker S; Sutter G
    J Virol; 2015 Aug; 89(16):8651-6. PubMed ID: 26018172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein.
    Li Y; Wan Y; Liu P; Zhao J; Lu G; Qi J; Wang Q; Lu X; Wu Y; Liu W; Zhang B; Yuen KY; Perlman S; Gao GF; Yan J
    Cell Res; 2015 Nov; 25(11):1237-49. PubMed ID: 26391698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS).
    Lu L; Xia S; Ying T; Jiang S
    Emerg Microbes Infect; 2015 Jun; 4(6):e37. PubMed ID: 26954884
    [No Abstract]   [Full Text] [Related]  

  • 10. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
    Malczyk AH; Kupke A; Prüfer S; Scheuplein VA; Hutzler S; Kreuz D; Beissert T; Bauer S; Hubich-Rau S; Tondera C; Eldin HS; Schmidt J; Vergara-Alert J; Süzer Y; Seifried J; Hanschmann KM; Kalinke U; Herold S; Sahin U; Cichutek K; Waibler Z; Eickmann M; Becker S; Mühlebach MD
    J Virol; 2015 Nov; 89(22):11654-67. PubMed ID: 26355094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus.
    Deng Y; Lan J; Bao L; Huang B; Ye F; Chen Y; Yao Y; Wang W; Qin C; Tan W
    Emerg Microbes Infect; 2018 Apr; 7(1):60. PubMed ID: 29618723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus.
    Corti D; Zhao J; Pedotti M; Simonelli L; Agnihothram S; Fett C; Fernandez-Rodriguez B; Foglierini M; Agatic G; Vanzetta F; Gopal R; Langrish CJ; Barrett NA; Sallusto F; Baric RS; Varani L; Zambon M; Perlman S; Lanzavecchia A
    Proc Natl Acad Sci U S A; 2015 Aug; 112(33):10473-8. PubMed ID: 26216974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels.
    Haagmans BL; van den Brand JM; Raj VS; Volz A; Wohlsein P; Smits SL; Schipper D; Bestebroer TM; Okba N; Fux R; Bensaid A; Solanes Foz D; Kuiken T; Baumgärtner W; Segalés J; Sutter G; Osterhaus AD
    Science; 2016 Jan; 351(6268):77-81. PubMed ID: 26678878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell Attachment Domains of the Porcine Epidemic Diarrhea Virus Spike Protein Are Key Targets of Neutralizing Antibodies.
    Li C; Li W; Lucio de Esesarte E; Guo H; van den Elzen P; Aarts E; van den Born E; Rottier PJM; Bosch BJ
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28381581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.
    Zhang N; Channappanavar R; Ma C; Wang L; Tang J; Garron T; Tao X; Tasneem S; Lu L; Tseng CT; Zhou Y; Perlman S; Jiang S; Du L
    Cell Mol Immunol; 2016 Mar; 13(2):180-90. PubMed ID: 25640653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.
    Al-Amri SS; Abbas AT; Siddiq LA; Alghamdi A; Sanki MA; Al-Muhanna MK; Alhabbab RY; Azhar EI; Li X; Hashem AM
    Sci Rep; 2017 Mar; 7():44875. PubMed ID: 28332568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein.
    Li W; Hulswit RJG; Widjaja I; Raj VS; McBride R; Peng W; Widagdo W; Tortorici MA; van Dieren B; Lang Y; van Lent JWM; Paulson JC; de Haan CAM; de Groot RJ; van Kuppeveld FJM; Haagmans BL; Bosch BJ
    Proc Natl Acad Sci U S A; 2017 Oct; 114(40):E8508-E8517. PubMed ID: 28923942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.
    Wang Y; Tai W; Yang J; Zhao G; Sun S; Tseng CK; Jiang S; Zhou Y; Du L; Gao J
    Hum Vaccin Immunother; 2017 Jul; 13(7):1615-1624. PubMed ID: 28277821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents.
    Yang Y; Deng Y; Wen B; Wang H; Meng X; Lan J; Gao GF; Tan W
    Viral Immunol; 2014 Dec; 27(10):543-50. PubMed ID: 25387086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the Receptor-Binding Domain of the Spike Glycoprotein of Human Betacoronavirus HKU1.
    Qian Z; Ou X; Góes LG; Osborne C; Castano A; Holmes KV; Dominguez SR
    J Virol; 2015 Sep; 89(17):8816-27. PubMed ID: 26085157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.